CoChat
Sign Up
Cited by 94

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Sigma-2 ligands induce tumour cell death by multiple signalling pathways

Zeng, C, Rothfuss, J, Zhang, J, Chu, W, Vangveravong, S, Tu, Z, Pan, F, Chang, K C, Hotchkiss, R, Mach, R H·2012·British Journal of Cancer
DOI 10.1038/bjc.2011.602PMC PMC3322954
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2011.602

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some small molecule modulators of S2R, such as siramesine and SV119, trigger the induction of autophagy, while other S2R modulators such as CT2168 can restore α-synuclein oligomer-induced deficits in lysosomal-associated membrane protein 2A levels back to healthy control levels in neurons.

    “Some small molecule modulators of S2R, such as siramesine and SV119, trigger the induction of autophagy [118,120], while other S2R modulators such as CT2168 can restore α-synuclein oligomer-induced deficits in lysosomal-associated membrane protein 2A levels, an indirect marker of autophagy, back to healthy control levels in neurons [4].”

    From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [118]

  • Treatment with S2R ligands induces processing of LC3, formation of autophagic vacuoles, and expression of downstream effectors of the mammalian Target of Rapamycin (mTOR) pathway.

    “Treatment with S2R ligands induces processing of LC3, formation of autophagic vacuoles, and expression of downstream effectors of the mammalian Target of Rapamycin (mTOR) pathway [118].”

    From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [118]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Cell cycle, CDKs and cancer: a changing paradigm

    Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 3×

    “It is well known that D-type cyclins are responsible for progression through G1 phase; E-type cyclins for completion of G1 phase and entry into S-phase; A-type cyclins for driving the transition from S-phase to M-phase (G2 phase); and B-type cyclins for cell progression through M-phase (Malumbres and Barbacid, 2009).”
    BackgroundInfluential

Flagged first, then by citations

Research works printed but not linked: 50

  1. Allan LA, Clarke PR (2007) Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 26: 301–310 · DOI
  2. Allan LA, Clarke PR (2008) A mechanism coupling cell division and the control of apoptosis. SEB Exp Biol Ser 59: 257–265
  3. Barbieri F, Sparatore A, Alama A, Novelli F, Bruzzo C, Sparatore F (2003) Novel sigma binding site ligands as inhibitors of cell proliferation in breast cancer. Oncol Res 13: 455–461 · DOI
  4. Barth S, Glick D, Macleod KF (2010) Autophagy: assays and artifacts. J Pathol 221: 117–124 · DOI
  5. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, Coscia CJ (1991) Overexpression of sigma receptors in nonneural human tumors. Cancer Res 51: 6558–6562
  6. Brent PJ, Pang G, Little G, Dosen PJ, Van Helden DF (1996) The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun 219: 219–226 · DOI
  7. Caldon CE, Musgrove EA (2010) Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div 5: 2 · DOI
  8. Cassano G, Gasparre G, Niso M, Contino M, Scalera V, Colabufo NA (2009) F281, synthetic agonist of the sigma-2 receptor, induces Ca2+ efflux from the endoplasmic reticulum and mitochondria in SK-N-SH cells. Cell Calcium 45: 340–345 · DOI · Paper page
  9. Caveliers V, Everaert H, Lahoutte T, Dierickx LO, John CS, Bossuyt A (2001) Labelled sigma receptor ligands: can their role in neurology and oncology be extended? Eur J Nucl Med 28: 133–135 · DOI
  10. Clarke PR, Allan LA (2009) Cell-cycle control in the face of damage – a matter of life or death. Trends Cell Biol 19: 89–98 · DOI
  11. Colabufo NA, Berardi F, Contino M, Ferorelli S, Niso M, Perrone R, Pagliarulo A, Saponaro P, Pagliarulo V (2006) Correlation between sigma2 receptor protein expression and histopathologic grade in human bladder cancer. Cancer Lett 237: 83–88 · DOI
  12. Crawford KW, Bittman R, Chun J, Byun HS, Bowen WD (2003) Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol Biol (Noisy-le-grand) 49: 1017–1023
  13. Crawford KW, Bowen WD (2002) Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 62: 313–322
  14. Crawford KW, Coop A, Bowen WD (2002) Sigma(2) receptors regulate changes in sphingolipid levels in breast tumor cells. Eur J Pharmacol 443: 207–209 · DOI
  15. Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E (2007) Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 102: 869–877 · DOI
  16. Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. J Pathol 221: 3–12 · DOI
  17. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H (1996) Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 93: 8072–8077 · DOI
  18. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD (1994) Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 268: 9–18 · DOI · Paper page
  19. Jacobson MD, Weil M, Raff MC (1997) Programmed cell death in animal development. Cell 88: 347–354 · DOI
  20. Janku F, McConkey DJ, Hong DS, Kurzrock R (2011) Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8: 528–539 · DOI
  21. John CS, Gulden ME, Li J, Bowen WD, McAfee JG, Thakur ML (1998) Synthesis, in vitro binding, and tissue distribution of radioiodinated 2-[125I]N-(N-benzylpiperidin-4-yl)-2-iodo benzamide, 2-[125I]BP: a potential sigma receptor marker for human prostate tumors. Nucl Med Biol 25: 189–194 · DOI
  22. Kashiwagi H, McDunn JE, Simon Jr PO, Goedegebuure PS, Vangveravong S, Chang K, Hotchkiss RS, Mach RH, Hawkins WG (2009) Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med 7: 24 · DOI
  23. Kashiwagi H, McDunn JE, Simon Jr PO, Goedegebuure PS, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss RS, Mach RH, Hawkins WG (2007) Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 6: 48 · DOI
  24. Kawamura K, Elsinga PH, Kobayashi T, Ishii S, Wang WF, Matsuno K, Vaalburg W, Ishiwata K (2003) Synthesis and evaluation of 11C- and 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol 30: 273–284 · DOI
  25. Li CY, Wang EQ, Cheng Y, Bao JK (2011) Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 43: 701–704 · DOI
  26. Mach RH, Huang Y, Buchheimer N, Kuhner R, Wu L, Morton TE, Wang L, Ehrenkaufer RL, Wallen CA, Wheeler KT (2001a) [(18)F]N-(4′-fluorobenzyl)-4-(3-bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [(18)F]FDG, and [(125)I]IUDR. Nucl Med Biol 28: 451–458 · DOI
  27. Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR (2004) Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. Bioorg Med Chem Lett 14: 195–202 · DOI
  28. Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT (1997) Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 57: 156–161
  29. Mach RH, Vangveravong S, Huang Y, Yang B, Blair JB, Wu L (2003) Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3a-yl phenylcarbamate analogs as sigma-2 receptor ligands. Med Chem Res 11: 380–398
  30. Mach RH, Yang B, Wu L, Kuhner R, Whirrett B, West T (2001b) Synthesis and sigma receptor binding affinities of 8-azabicyclo[3.2.1]octan-3a-yl and 9-azabicyclo[3.3.1]nonan-3a-yl phenyl carbamates. Med Chem Res 10: 339–355
  31. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222–231 · DOI
  32. Malumbres M, Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630–641 · DOI
  33. Megalizzi V, Le Mercier M, Decaestecker C (2010) Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy. Med Res Rev; e-pub ahead of print 4 August 2010; doi:10.1002/med.20218 · DOI
  34. Miyazaki T, Arai S (2007) Two distinct controls of mitotic cdk1/cyclin B1 activity requisite for cell growth prior to cell division. Cell Cycle 6: 1419–1425 · DOI
  35. Moretti L, Cha YI, Niermann KJ, Lu B (2007) Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress? Cell Cycle 6: 793–798 · DOI
  36. Musgrove EA (2006) Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24: 13–19 · DOI
  37. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M (2005) Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 65: 8975–8983 · DOI
  38. Ostenfeld MS, Hoyer-Hansen M, Bastholm L, Fehrenbacher N, Olsen OD, Groth-Pedersen L, Puustinen P, Kirkegaard-Sorensen T, Nylandsted J, Farkas T, Jaattela M (2008) Anticancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 4: 487–499 · DOI · Paper page
  39. Platini F, Perez-Tomas R, Ambrosio S, Tessitore L (2010) Understanding autophagy in cell death control. Curr Pharm Des 16: 101–113 · DOI
  40. Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1: 111–121 · DOI
  41. Roperto S, Colabufo NA, Inglese C, Urraro C, Brun R, Mezza E, Staibano S, Raso C, Maiolino P, Russo V, Palma E, Roperto F (2010) Sigma-2 receptor expression in bovine papillomavirus-associated urinary bladder tumours. J Comp Pathol 142: 19–26 · DOI
  42. Seth P, Leibach FH, Ganapathy V (1997) Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem Biophys Res Commun 241: 535–540 · DOI
  43. Vilner BJ, John CS, Bowen WD (1995) Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55: 408–413
  44. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC (1990) Sigma receptors: biology and function. Pharmacol Rev 42: 355–402 · DOI
  45. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH (2000) Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 82: 1223–1232 · DOI · Paper page
  46. Witzel II, Koh LF, Perkins ND (2010) Regulation of cyclin D1 gene expression. Biochem Soc Trans 38: 217–222 · DOI
  47. Wyllie AH (2010) ‘Where, O death, is thy sting?’ A brief review of apoptosis biology. Mol Neurobiol 42: 4–9 · DOI
  48. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, Johnston F, Spitzer D, Chang KC, Hotchkiss RS, Hawkins WG, Wheeler KT, Mach RH (2011) Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2: 380 · DOI · Paper page
  49. Zeng C, Vangveravong S, Jones LA, Hyrc K, Chang KC, Xu J, Rothfuss JM, Goldberg MP, Hotchkiss RS, Mach RH (2011) Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Mol Imaging 10: 420–433 · DOI
  50. Zeng C, Vangveravong S, Xu J, Chang KC, Hotchkiss RS, Wheeler KT, Shen D, Zhuang ZP, Kung HF, Mach RH (2007) Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res 67: 6708–6716 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zeng, C., Rothfuss, J., Zhang, J., Chu, W., Vangveravong, S., Tu, Z., Pan, F., Chang, K. C., Hotchkiss, R., & Mach, R. H.
Venue
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Published
2012-01-17
Volume
106
Issue
4
Pages
693-701
ISSN
  • 0007-0920
  • 1532-1827
DOI
10.1038/bjc.2011.602
PMC
PMC3322954
Cited by
94
References
1
Language
en
Licence
www.springer.com/tdm (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review